Evidence map›Paper›PMID 40166828›Full record

ArticleCirculation2025

Olmesartan Restores

Eric J Kort, Nazish Sayed, Chun Liu, Gema Mondéjar-Parreño, Jens Forsberg, Emily Eugster, Sean M Wu, Joseph C Wu, Stefan Jovinge

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Circulation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Eric J Kort *DeVos Cardiovascular Research Program, Fredrik Meijer Heart and Vascular Institute, Spectrum Health and Van Andel Institute, Grand Rapids, MI (E.J.K., J.F., E.E., S.J.).
Nazish Sayed *Cardiovascular Institute, Stanford University, CA (N.S., C.L., G.M.-P., S.M.W., J.C.W., S.J.).ORCID 0000-0002-8229-721X
Chun LiuCardiovascular Institute, Stanford University, CA (N.S., C.L., G.M.-P., S.M.W., J.C.W., S.J.).ORCID 0000-0002-8242-3896
Gema Mondéjar-ParreñoCardiovascular Institute, Stanford University, CA (N.S., C.L., G.M.-P., S.M.W., J.C.W., S.J.).
Jens ForsbergDeVos Cardiovascular Research Program, Fredrik Meijer Heart and Vascular Institute, Spectrum Health and Van Andel Institute, Grand Rapids, MI (E.J.K., J.F., E.E., S.J.).
Emily EugsterDeVos Cardiovascular Research Program, Fredrik Meijer Heart and Vascular Institute, Spectrum Health and Van Andel Institute, Grand Rapids, MI (E.J.K., J.F., E.E., S.J.).
Sean M WuCardiovascular Institute, Stanford University, CA (N.S., C.L., G.M.-P., S.M.W., J.C.W., S.J.).ORCID 0000-0002-0000-3821
Joseph C WuCardiovascular Institute, Stanford University, CA (N.S., C.L., G.M.-P., S.M.W., J.C.W., S.J.).ORCID 0000-0002-6068-8041
Stefan JovingeDeVos Cardiovascular Research Program, Fredrik Meijer Heart and Vascular Institute, Spectrum Health and Van Andel Institute, Grand Rapids, MI (E.J.K., J.F., E.E., S.J.).ORCID 0000-0002-8446-0228

Funding

Elucidating ECM Signaling in Cardiac Organoids with Machine Learning and Single-cell MultiomicsR01HL163680 · NHLBI · STANFORD UNIVERSITY · PI RAJADAS, JAYAKUMAR, WONG, WING H. · 2022 to 2025
$2.5M
Deciphering the Endothelial Cell-Cardiomyocyte Crosstalk in LMNA CardiomyopathyR01HL158641 · NHLBI · STANFORD UNIVERSITY · PI SAYED, NAZISH · 2021 to 2025
$2.2M
Unraveling the role of endothelium in chemotherapy-induced cardiotoxicityR01HL161002 · NHLBI · STANFORD UNIVERSITY · PI SAYED, NAZISH · 2022 to 2025
$1.6M
NHLBI NIH HHS R01 HL158641NHLBI NIH HHS R01 HL161002NHLBI NIH HHS R01 HL163680
6 · The paper itself

Abstract

backgroundGene mutations are responsible for a sizeable proportion of cases of heart failure. However, the number of patients with any specific mutation is small. Repositioning of existing US Food and Drug Administration-approved compounds to target specific mutations is a promising approach to efficient identification of new therapies for these patients.

methodsThe National Institutes of Health Library of Integrated Network-Based Cellular Signatures database was interrogated to identify US Food and Drug Administration-approved compounds that demonstrated the ability to reverse the transcriptional effects of

resultsSeveral angiotensin receptor blockers were identified from our in silico screen. Of these, olmesartan significantly elevated the expression of sarcomeric genes and rate and force of contraction and ameliorated arrhythmogenic potential. In addition, olmesartan exhibited the ability to reduce phosphorylation of extracellular signal-regulated kinase 1 in

conclusionsIn silico screening followed by in vitro validation with induced pluripotent stem cell-derived models can be an efficient approach to identifying repositionable therapies for monogenic cardiomyopathies.

Indexed as

Angiotensin II Type 1 Receptor BlockersHaploinsufficiencyImidazolesLamin Type AMyocytes, CardiacTetrazolesCells, CulturedHumansInduced Pluripotent Stem CellsAngiotensin II Type 1 Receptor BlockersImidazolesLamin Type ALMNA protein, humanolmesartanTetrazolescardiomyopathiesdrug repositioninggene expression profilinglamins

Identifiers

PMID40166828
PMCPMC12084018

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.